Sippican Capital Advisors buys $640,895 stake in Pfizer (PFE)

Pfizer (PFE) : Sippican Capital Advisors scooped up 3,086 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 17,392 shares of Pfizer which is valued at $640,895.Pfizer makes up approximately 0.73% of Sippican Capital Advisors’s portfolio.

Other Hedge Funds, Including , Prospera Financial Services Inc boosted its stake in PFE in the latest quarter, The investment management firm added 2,423 additional shares and now holds a total of 25,905 shares of Pfizer which is valued at $954,599. Pfizer makes up approx 0.19% of Prospera Financial Services Inc’s portfolio.Mcqueen Ball Associates boosted its stake in PFE in the latest quarter, The investment management firm added 360 additional shares and now holds a total of 58,397 shares of Pfizer which is valued at $2,145,506. Pfizer makes up approx 1.48% of Mcqueen Ball Associates’s portfolio.Evanson Asset Management reduced its stake in PFE by selling 315 shares or 2.31% in the most recent quarter. The Hedge Fund company now holds 13,320 shares of PFE which is valued at $488,578. Pfizer makes up approx 0.14% of Evanson Asset Management’s portfolio.Breton Hill Capital Ltd. boosted its stake in PFE in the latest quarter, The investment management firm added 7,578 additional shares and now holds a total of 24,666 shares of Pfizer which is valued at $895,622. Pfizer makes up approx 0.28% of Breton Hill Capital Ltd.’s portfolio.Berson Corrado Investment Advisors reduced its stake in PFE by selling 250 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 34,984 shares of PFE which is valued at $1,263,622. Pfizer makes up approx 0.47% of Berson Corrado Investment Advisors’s portfolio.

Pfizer opened for trading at $36.68 and hit $36.95 on the upside on Friday, eventually ending the session at $36.89, with a gain of 0.60% or 0.22 points. The heightened volatility saw the trading volume jump to 2,15,13,828 shares. Company has a market cap of $223,732 M.

On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Investors should note that on Jun 23, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Aug 3, 2016 as the ex-dividend date and fixed the record date on Aug 5, 2016. The payable date has been fixed on Sep 1, 2016.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *